Last updated: October 7, 2026
A positive margin means cancer cells reach the outer edge of the tissue removed during surgery, so some tumour may remain in the body. Positive margins after basal cell carcinoma excision do not mean the cancer has spread to other organs. For most basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) cases, the usual next step is re-excision or Mohs micrographic surgery, though some low-risk cases are monitored closely instead.
A positive margin means the pathologist found cancer cells at or touching the outer edge of the tissue sample, which suggests the surgeon may not have removed all of the tumour in one pass. This finding comes directly from microscopic examination of the specimen border, not from how the wound looks on the skin.
The report is generated after the tissue is processed in a lab, sliced thin, and reviewed under a microscope by a pathologist. Surgical margins are measured in millimetres from the visible tumour edge to the cut edge of tissue. When no cancer cells are found at that boundary, the margin is called "negative" or "clear." When cancer cells are seen right at the boundary, the margin is called "positive" or "involved." For a full walkthrough of pathology terminology, see the plain-English guide to pathology reports.
Margin status falls into three practical categories that guide what happens next: clear, close, and involved (positive). Each one changes the level of concern and the recommended follow-up.
Example: a BCC removed from the nose with a 2 mm clearance on all sides is clear. The same tumour with cancer cells visible right at one edge of the specimen is positive, even if the rest of the margin looks clean.
Positive margins are not rare; reported rates vary by surgical technique, tumour site, and surgeon experience, generally landing in a range that most dermatologic and surgical literature treats as expected rather than exceptional [2][9]. Facial sites with tight anatomy, such as the nose, ears, and eyelids, tend to show higher positive-margin rates because surgeons must balance complete removal against preserving function and appearance [5][9].
A 2025 surgical cohort looking at margins and reoperation found that certain tumour and technique factors predictably pushed cases toward re-intervention, reinforcing that positive margins are a recognized, trackable part of routine excisional care rather than an unusual complication [2].
A positive margin raises the risk of local recurrence but does not automatically mean the cancer will return, and it does not indicate the cancer has spread to lymph nodes or distant organs. Some positive margins reflect a thin shave of reactive tissue rather than true residual tumour, so the finding carries risk without being a certainty of recurrence [1].
Untreated positive margins carry real downsides over time, including a larger, more invasive tumour if growth continues undetected, and in SCC specifically, a higher chance of local tissue damage or, less commonly, perineural invasion [6]. This is why most skin cancer teams recommend addressing a positive margin rather than ignoring it, even when the tumour is a low-risk subtype. For more on how BCC behaves if left alone, see does basal cell carcinoma spread.
Published recurrence rates after positive-margin BCC vary by study, follow-up length, and tumour subtype, and no single universal percentage applies to every patient. Studies tracking incompletely excised BCC over several years have found that recurrence can appear well beyond the first 12 months, which is why long-term follow-up is recommended rather than a single post-surgical check [8].
Because recurrence risk depends heavily on tumour location, subtype (nodular versus infiltrative or morpheaform), and how much tumour was left behind, a treating surgeon is the right source for a personalized estimate rather than a generic published rate.
Most patients with a positive margin after BCC or SCC excision will be offered re-excision or Mohs micrographic surgery, since removing the remaining tumour lowers the chance of local regrowth. A smaller group of low-risk cases may be watched closely instead of being re-cut immediately.
Tumour typeUsual next stepWhen monitoring may be consideredWhen Mohs is preferredLow-risk BCC (small, superficial, trunk/limbs)Re-excision or close monitoringElderly patient, limited life expectancy, very low-risk subtype [7]Rarely neededHigh-risk BCC (face, recurrent, infiltrative subtype)Re-excision or Mohs surgeryRarely appropriatePreferred for central face, eyelids, nose, earsLow-risk SCCRe-excisionSelect cases with poor surgical candidacy, discussed with surgeonNot typically requiredHigh-risk SCC (perineural invasion, poorly differentiated, recurrent)Mohs surgery or wide re-excisionNot usually appropriateStrongly preferred [10]
For a deeper comparison of excision, Mohs, and curettage for SCC, review SCC treatment: excision versus Mohs versus curettage. Current guideline-level reviews from Europe generally favour re-excision over radiotherapy as the first-line response to a positive margin when surgery remains feasible [4].
A re-excision removes an additional ring of tissue around and sometimes beneath the original scar to capture any remaining tumour cells, and it is performed under local anesthetic in most cases. The amount of tissue removed depends on tumour type, prior margin status, and location, with guideline-based margins commonly ranging from a few millimetres for low-risk BCC to wider margins for high-risk or recurrent tumours [7].
The procedure follows a predictable pattern:
Recovery after re-excision resembles recovery from the first procedure; details are covered in BCC recovery: what to expect after removal.
Mohs micrographic surgery checks 100 percent of the tissue margin during the procedure itself, which is why it produces lower positive-margin rates than standard excision for many high-risk tumours [10]. Standard excision typically samples only a fraction of the margin under the microscope afterward, so a positive margin can be discovered only after the patient has already left the clinic.
Choose Mohs if the tumour sits on the central face, nose, eyelids, ears, or lips, is recurrent, or shows aggressive features on biopsy, since margin control in these tight cosmetic zones matters more than in other body sites [10]. Standard excision remains reasonable for most low-risk BCC and SCC on the trunk or limbs, where margin requirements are more forgiving.
Topical treatments such as imiquimod or 5-fluorouracil are not standard treatment for a confirmed positive margin after surgical excision, because they are designed for superficial, biopsy-proven BCC that has not already been surgically cut. Once a tumour has been excised and shown positive margins, topical therapy does not reliably reach residual tumour cells that may sit deeper in the scar tissue.
Surgeons generally reserve topical options for specific low-risk superficial BCC scenarios discussed before any surgery, not as a substitute for re-excision or Mohs surgery after a positive-margin pathology result.
Margins can come back positive because of tumour-related factors, such as an infiltrative growth pattern that extends beyond what is visible to the eye, or because of factors related to the removal technique itself. Operator experience and specialty training strongly influence positive-margin rates, with higher-volume, specialty-trained surgeons generally reporting lower rates on comparable tumours [9].
Common contributing factors include:
This is why a positive margin is usually framed as a known risk of the procedure rather than an error, and it is a reasonable topic to raise directly with the treating surgeon.
Standard excision pathology results typically take about one to two weeks to come back, since the tissue must be processed, sliced, stained, and reviewed by a pathologist before the report is finalized. Mohs micrographic surgery is different: margins are checked in real time during the same visit, so results are available within hours rather than weeks.
Patients having standard excision for BCC or SCC should expect a follow-up call or appointment once the report is ready, and should ask in advance how results will be communicated and what the next step will be if margins come back positive.
A positive margin found weeks after the original surgery is managed the same way as one caught earlier, with re-excision or Mohs surgery usually recommended once the report is reviewed. The short delay in receiving lab results does not meaningfully change outcomes for most BCC and SCC cases, since these tumours generally grow slowly compared with other cancer types [6].
The practical difference is scheduling: the surgeon will typically book a re-excision visit once the scar has healed enough to be safely re-opened, often a few weeks after the original procedure. Waiting for proper healing before re-excision is standard practice and is not considered a delay in care.
Yes. Treatment for BCC and SCC in Ontario, including the original excision and any follow-up re-excision for positive margins, is covered under OHIP when performed by a physician for a medically necessary reason. Patients do not pay out of pocket for medically required skin cancer surgery in the province.
The Minor Surgery Center removes BCC and SCC with OHIP coverage at its GTA clinics, including the York Mills skin cancer removal location and through its squamous cell carcinoma treatment program. Confirming OHIP coverage and referral requirements directly with the clinic or treating surgeon is the most reliable way to plan next steps.
Beyond margin status, a few pathology terms change how aggressively a BCC or SCC needs to be managed and are worth asking about directly. These terms describe how the tumour behaves, not just where its edges sit.
Asking the treating surgeon to explain each of these terms in the context of a specific pathology report is a reasonable and expected part of follow-up care.
Does a positive margin mean the cancer has spread?
No. A positive margin means cancer cells were found at the edge of the removed tissue sample, which is a local finding about the surgical site, not evidence that cancer has travelled to lymph nodes or other organs.
Will I definitely need another surgery for a positive margin?
Most positive-margin BCC and SCC cases are managed with re-excision or Mohs micrographic surgery, though a small number of low-risk, superficial BCC cases may be monitored instead, depending on the surgeon's assessment.
How soon after the first surgery can re-excision happen?
Re-excision is usually scheduled once the original wound has healed enough to be safely reopened, which is often a few weeks after the first procedure.
Is Mohs surgery always better than standard excision for positive margins?
Mohs surgery produces lower positive-margin rates for high-risk facial tumours because it checks the entire margin during the procedure, but standard excision remains appropriate for many low-risk tumours on the trunk and limbs [10].
Does OHIP cover the cost of re-excision in Ontario?
Yes, medically necessary BCC and SCC treatment, including re-excision after positive margins, is covered under OHIP for Ontario residents.
What should I do right after reading "positive margin" on my report?
Book a follow-up appointment with the treating surgeon to discuss tumour subtype, margin distance, and whether re-excision, Mohs surgery, or monitoring is the recommended next step.
Positive margins after basal cell carcinoma excision describe a specific, well-documented pathology finding: tumour cells reaching the cut edge of the removed tissue. The finding raises the chance of local regrowth but does not mean the cancer has spread, and it is common enough in routine skin cancer surgery that most treatment teams have a standard protocol for handling it, usually re-excision or Mohs micrographic surgery. Reviewing the full pathology report, asking about tumour subtype and margin distance, and confirming OHIP coverage for any follow-up procedure are the most useful next steps. This article provides general information only; decisions about re-excision, Mohs surgery, or monitoring should be made directly with the treating surgeon based on the specific pathology report and tumour characteristics.
[1] Pmc4516103 - https://pmc.ncbi.nlm.nih.gov/articles/PMC4516103/
[2] onlinelibrary.wiley - https://onlinelibrary.wiley.com/doi/10.1111/ans.70197
[3] onlinelibrary.wiley - https://onlinelibrary.wiley.com/doi/10.5402/2012/246542
[4] Es Revista Medicina Familia Semergen 40 Pdf Download S157821901300005x - https://www.elsevier.es/es-revista-medicina-familia-semergen-40-pdf-download-S157821901300005X
[5] Pmc3135095 - https://pmc.ncbi.nlm.nih.gov/articles/PMC3135095/
[6] Nbk482439 - https://www.ncbi.nlm.nih.gov/books/NBK482439/
[7] Non Melanoma Skin Cancer United Kingdom National Multidisciplinary Guidelines - https://www.cambridge.org/core/services/aop-cambridge-core/content/view/EC5EF7B3A87F26984E49F02239E1AD31/S0022215116000554a.pdf/non-melanoma-skin-cancer-united-kingdom-national-multidisciplinary-guidelines.pdf
[8] Pmc10598491 - https://pmc.ncbi.nlm.nih.gov/articles/PMC10598491/
[9] Pmc3661037 - https://pmc.ncbi.nlm.nih.gov/articles/PMC3661037/
[10] Pmc5312180 - https://pmc.ncbi.nlm.nih.gov/articles/PMC5312180/
